Stayble Therapeutics reports top-line data from the company's phase IIb study
Stayble Therapeutics AB ("Stayble" or the "Company") today presents top-line data from the Company's phase IIb study with STA363 for the treatment of degenerative disc disease, "DDD". The randomized, double-blind study did not meet the primary objective. According to the pre-specified statistical criteria, STA363 compared to placebo did not show a statistically significant reduction in pain at six months.The study was a randomized, double-blind, placebo-controlled concept study investigating the efficacy and safety of two concentrations of STA363 (60 and 120 mg/ml) compared to placebo in